What is Cannabis Hyperemesis Syndrome?

Cannabis Hyperemesis Syndrome (CHS) is a paradoxical condition observed in chronic cannabis users, characterized by recurrent, intractable episodes of nausea and vomiting (emesis). While cannabis is frequently used as an antiemetic, long-term recreational or medicinal use can, in a subset of individuals, produce a severe cyclic vomiting disorder. The syndrome typically resolves only after sustained abstinence from cannabis, although the reasons for this paradoxical reaction remain under investigation.

Although emesis is the hallmark complaint, patients frequently report a range of autonomic and neurological symptoms. Among these, dizziness and lightheadedness are common, raising important clinical questions about the interaction between the endocannabinoid system, the vestibular apparatus, and the brainstem pathways that coordinate both balance and the vomiting reflex.

The Otoneurological Connection to Dizziness

Otoneurology is the medical subspecialty that bridges otolaryngology and neurology, focusing on the evaluation and management of dizziness, vertigo, imbalance, and disorders of the inner ear and their central connections. In patients with CHS, the relationship between the gut, the inner ear, and the brain is not always straightforward. Cannabinoid receptors (CB1 and CB2) are distributed widely throughout the central nervous system, including regions of the brainstem involved in vestibular processing and the vomiting centers of the medulla.

Dizziness in the setting of CHS may be multifactorial. Repeated episodes of severe vomiting can lead to electrolyte disturbances, dehydration, and orthostatic hypotension, producing a sensation of lightheadedness rather than true rotational vertigo. However, some patients experience genuine vestibular-type symptoms, suggesting a central or peripheral otoneurological effect of cannabinoid toxicity. The endocannabinoid system is known to modulate the activity of vestibular nuclei, and chronic cannabis exposure may disrupt this balance, causing a disordered perception of motion.

Emesis and the Endocannabinoid System in CHS

The vomiting reflex is regulated by a complex network involving the chemoreceptor trigger zone (CTZ), the nucleus tractus solitarius, and the vagus nerve. Cannabinoids act on CB1 receptors in the dorsal vagal complex and elsewhere to suppress vomiting in most clinical contexts. In CHS, however, chronic high-dose cannabis exposure is thought to produce a state of dysregulation, possibly involving altered receptor down-regulation, genetic susceptibility, or toxic metabolic accumulation.

Clinically, the emesis in CHS is notable for several features:

• Cyclical episodes of severe, intractable nausea and vomiting that may last for hours to days.
• A compulsion to take hot baths or showers, which paradoxically provides temporary relief from vomiting and abdominal discomfort.
• Symptom resolution typically occurring only after complete cessation of cannabis use.
• A prodromal phase of early-morning nausea and abdominal cramping that precedes the hyperemetic phase.

Diagnostic Challenges and the Role of Otoneurology

The diagnosis of CHS is frequently delayed, as patients often undergo extensive gastroenterological and abdominal imaging before the pattern of marijuana use is recognized. In patients presenting with dizziness alongside cyclical vomiting, the otoneurological evaluation is crucial to rule out other vestibular disorders such as Ménière's disease, episodic ataxia, vestibular migraine, or posterior fossa pathology.

Assessment typically includes a thorough history of cannabis consumption, including frequency, dose, and duration of use. Vestibular testing, including videonystagmography, positional testing, and caloric testing, may be performed in selected patients when vertigo is a prominent feature. However, in classic CHS, otoneurological findings are often normal between episodes, apart from signs of postural instability related to general debilitation during attacks.

Clinicians should maintain a high index of suspicion in young to middle-aged adults with recurrent vomiting and unexplained dizziness who report regular cannabis use. Screening for cannabis use should be part of the routine assessment of any patient with unexplained cyclic emesis or vertiginous complaints, particularly where abdominal pain is prominent.

Management and Treatment Approaches

The cornerstone of treatment remains total abstinence from cannabis. Patients who discontinue use typically observe gradual improvement within days, although post-emetic symptoms such as fatigue and mild dizziness may persist for several weeks as the endocannabinoid system resets.

During acute hyperemetic episodes, supportive therapy is essential. Intravenous hydration and electrolyte replacement address the consequences of prolonged vomiting. Antiemetic drugs commonly used for other causes of vomiting (such as dopamine antagonists or serotonin antagonists) are frequently ineffective in CHS. However, capsaicin cream applied topically to the abdomen has shown promise, as it is believed to desensitize TRPV1 receptors, which are implicated in the regulation of nausea and the gut-brain axis. Lorazepam and other benzodiazepines may provide symptomatic relief in some patients.

For the otoneurological component, dizziness is often managed symptomatically during acute episodes with hydration and rest. Vestibular suppressants may be considered on a case-by-case basis, though they are not specifically validated for CHS. Long-term follow-up should include patient education, behavioral counseling, and monitoring for relapse, particularly given the widespread availability and social acceptance of cannabis products.

Conclusion

Cannabis Hyperemesis Syndrome represents a unique clinical paradox in which a substance commonly used to treat nausea and vomiting paradoxically induces a severe cyclic vomiting disorder in chronic users. The intersection of emesis, dizziness, and autonomic instability places this condition squarely within the clinical interests of otoneurology, particularly when vestibular symptoms are prominent. Recognition of the syndrome requires careful attention to the patient's cannabis history, and successful treatment rests upon sustained cessation.

There is an ongoing need for broader awareness of CHS among clinicians in emergency medicine, gastroenterology, primary care, and otoneurology. Early diagnosis not only shortens the burden of suffering for patients but reduces the cost and invasiveness of unnecessary investigations. Clinicians in balance disorders and dizziness clinics should be reminded that, for a subset of chronic cannabis users, the source of their disabling vomiting and disequilibrium may lie not in the inner ear itself, but in the very substance they use to relieve their symptoms.